A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer

Jianliang Shen; Han Cheon Kim; Joy Wolfram; Chaofeng Mu; Wei Zhang; Haoran Liu; Yan Xie; Junhua Mai; Hang Zhang; Zhi Li; Maria Guevara; Zong Wan Mao; Haifa Shen

doi:10.1021/acs.nanolett.7b00132

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer

Jianliang Shen, Han Cheon Kim, Joy Wolfram, Chaofeng Mu, Wei Zhang, Haoran Liu, Yan Xie, Junhua Mai, Hang Zhang, Zhi Li, Maria Guevara, Zong Wan Mao, Haifa Shen

Research output: Contribution to journal › Article › peer-review

120 Scopus citations

Abstract

Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)₂dppz](ClO₄)₂ (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

Original language	English (US)
Pages (from-to)	2913-2920
Number of pages	8
Journal	Nano Letters
Volume	17
Issue number	5
DOIs	https://doi.org/10.1021/acs.nanolett.7b00132
State	Published - May 10 2017

Keywords

Liposome
nanoplatform
ruthenium polypyridine complex
theranostic
triple-negative breast cancer

ASJC Scopus subject areas

Bioengineering
General Chemistry
General Materials Science
Condensed Matter Physics
Mechanical Engineering

Access to Document

10.1021/acs.nanolett.7b00132

Cite this

@article{d8bebc800c9e4414bc32a817aa170e7c,

title = "A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer",

abstract = "Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.",

keywords = "Liposome, nanoplatform, ruthenium polypyridine complex, theranostic, triple-negative breast cancer",

author = "Jianliang Shen and Kim, {Han Cheon} and Joy Wolfram and Chaofeng Mu and Wei Zhang and Haoran Liu and Yan Xie and Junhua Mai and Hang Zhang and Zhi Li and Maria Guevara and Mao, {Zong Wan} and Haifa Shen",

note = "Publisher Copyright: {\textcopyright} 2017 American Chemical Society.",

year = "2017",

month = may,

day = "10",

doi = "10.1021/acs.nanolett.7b00132",

language = "English (US)",

volume = "17",

pages = "2913--2920",

journal = "Nano Letters",

issn = "1530-6984",

publisher = "American Chemical Society",

number = "5",

}

TY - JOUR

T1 - A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer

AU - Shen, Jianliang

AU - Kim, Han Cheon

AU - Wolfram, Joy

AU - Mu, Chaofeng

AU - Zhang, Wei

AU - Liu, Haoran

AU - Xie, Yan

AU - Mai, Junhua

AU - Zhang, Hang

AU - Li, Zhi

AU - Guevara, Maria

AU - Mao, Zong Wan

AU - Shen, Haifa

PY - 2017/5/10

Y1 - 2017/5/10

N2 - Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

AB - Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

KW - Liposome

KW - nanoplatform

KW - ruthenium polypyridine complex

KW - theranostic

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85019211756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019211756&partnerID=8YFLogxK

U2 - 10.1021/acs.nanolett.7b00132

DO - 10.1021/acs.nanolett.7b00132

M3 - Article

C2 - 28418672

AN - SCOPUS:85019211756

SN - 1530-6984

VL - 17

SP - 2913

EP - 2920

JO - Nano Letters

JF - Nano Letters

IS - 5

ER -

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this